Video
Dr. Brufsky on the COLET Trial for Triple-Negative Breast Cancer
Author(s):
Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the COLET trial combining cobimetinib (Cotellic) and paclitaxel (Abraxane) as a treatment for patients with triple-negative breast cancer (TNBC).
Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the COLET trial combining cobimetinib (Cotellic) and paclitaxel (Abraxane) as a treatment for patients with triple-negative breast cancer (TNBC).
The aim of this study was to determine if there was any benefit of adding cobimetinib to paclitaxel and a PD-L1 inhibitor. The idea being that this will supposedly help regulate the PD-L1 inhibitor, explains Brufsky.
This study will inform us on next steps and future additional trials, says Brufsky. If adding cobimetinib to a PD-L1 inhibitor in TNBC tends to improve the response rate or other outcome measures without adding much toxicity, then the idea will be possibly adding cobimetinib to nanoparticle paclitaxel and atezolizumab (Tecentriq).
